Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine.

Abstract:

:1. We studied the effects of pre-treatment with oral indomethacin (25 mg four times daily for 3 days) on the pharmacokinetics, haemodynamics and diuretic properties of oral felodipine (10 mg single dose) in 12 healthy male volunteers using a placebo controlled double-blind four-way crossover protocol. 2. Felodipine with or without indomethacin pretreatment reduced standing diastolic blood pressure (P less than 0.001) at 0.5 to 3.0 h after dosing compared with placebo or indomethacin alone. Systolic blood pressures during indomethacin treatment alone were consistently higher than the other three treatment groups (P less than 0.01), presumably due to sodium and fluid retention. 3. Felodipine and felodipine plus indomethacin produced significantly greater excretion of urine and urinary sodium, but not of urinary potassium or creatinine when compared with placebo (P less than 0.01) over an 8 h period. 4. The pharmacokinetic parameters of felodipine (Cmax, tmax, t1/2 and AUC), the concentration-response curves for blood pressure lowering effects, the reflex tachycardia, diuretic properties and side-effects profile of felodipine were not significantly altered by indomethacin pretreatment in normal volunteers.

journal_name

Br J Clin Pharmacol

authors

Hardy BG,Bartle WR,Myers M,Bailey DG,Edgar B

doi

10.1111/j.1365-2125.1988.tb05295.x

subject

Has Abstract

pub_date

1988-11-01 00:00:00

pages

557-62

issue

5

eissn

0306-5251

issn

1365-2125

journal_volume

26

pub_type

临床试验,杂志文章
  • Bioactivation of dapsone to a cytotoxic metabolite: in vitro use of a novel two compartment system which contains human tissues.

    abstract::1. A two compartment system, comprising two adjacent teflon chambers separated by a semi-permeable membrane, has been devised with which to investigate the generation of drug metabolites that are toxic to human cells in vitro. 2. Compartment A contained a drug-metabolising system (human liver microsomes +/- NADPH) and...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1990.tb03793.x

    authors: Riley RJ,Roberts P,Coleman MD,Kitteringham NR,Park BK

    更新日期:1990-09-01 00:00:00

  • Assuming one dose per day yields a similar estimate of medication adherence in patients with stroke: An exploratory analysis using linked registry data.

    abstract:PURPOSE:Prescribed daily dose (PDD), the number of doses prescribed to be taken per day, is used to calculate medication adherence using pharmacy claims data. PDD can be substituted by (i) one dose per day (1DD), (ii) an estimate based on the 75th percentile of days taken by patients to refill a script (PDD75 ) or (iii...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14468

    authors: Ung D,Dalli LL,Lopez D,Sanfilippo FM,Kim J,Andrew NE,Thrift AG,Cadilhac DA,Anderson CS,Kilkenny MF

    更新日期:2020-07-08 00:00:00

  • Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.

    abstract:AIMS:The administration of omeprazole may interfere with the absorption of orally administered drugs by reducing gastric pH and hence tablet dissolution. The aim of this study was to investigate the effects of a 5 day administration of omeprazole on the pharmacokinetics of furazolidone. METHODS:Eighteen healthy (nine ...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.0306-5251.2001.01435.x

    authors: Calafatti SA,Ortiz RA,Deguer M,Martinez M,Pedrazzoli J Jr

    更新日期:2001-08-01 00:00:00

  • First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

    abstract:AIMS:SNF472 is a calcification inhibitor being developed for the treatment of cardiovascular calcification in haemodialysis (HD) and in calciphylaxis patients. This study investigated the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) SNF472 in healthy volunteers (HV) and HD patients. METHODS:This ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/bcp.13752

    authors: Perelló J,Joubert PH,Ferrer MD,Canals AZ,Sinha S,Salcedo C

    更新日期:2018-12-01 00:00:00

  • Lisinopril: dose-peak effect relationship in essential hypertension.

    abstract::1. The dose-peak effect relationship of lisinopril was evaluated in a double-blind, parallel study in 83 patients with mild to moderate essential hypertension (supine diastolic blood pressure = 95-115 mm Hg). 2. After a 4 week placebo washout, patients were randomly assigned to one of four treatments: lisinopril 2.5, ...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.1988.tb03342.x

    authors: Cirillo VJ,Gomez HJ,Salonen J,Salonen R,Rissanen V,Bolognese JA,Nyberg R,Kristianson K

    更新日期:1988-05-01 00:00:00

  • Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.

    abstract:AIMS:6-mercaptopurine (6-MP) is used in the treatment of childhood acute lymphoblastic leukaemia (ALL). Its red blood cell (RBC) metabolite concentrations (6-thioguanine [6-TGN] and 6-methylmercaptopurine nucleotides [6-MMPN]) are related to drug response. We investigated the impact of non-genetic covariates and pharma...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.2010.03867.x

    authors: Adam de Beaumais T,Fakhoury M,Medard Y,Azougagh S,Zhang D,Yakouben K,Jacqz-Aigrain E

    更新日期:2011-04-01 00:00:00

  • Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

    abstract::WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Dihydropyrimidine dehydrogenase (DPD) is the enzyme responsible for the elimination of approximately 80% of the administered dose of 5-fluorouracil (5-FU). * Mutations in the DPD-coding gene have been shown to increase the risk of severe toxicity in 5-FU treated patients. * T...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.2010.03683.x

    authors: Paré L,Paez D,Salazar J,Del Rio E,Tizzano E,Marcuello E,Baiget M

    更新日期:2010-08-01 00:00:00

  • Gender differences in clinical registration trials: is there a real problem?

    abstract:AIMS:Several studies have reported the under-representation of women in clinical trials, thereby challenging the external validity of the benefit/risk assessments of launched drugs. Our aim was to determine the extent to which women have been included in clinical trials used for drug registration and to analyse the fra...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.13497

    authors: Labots G,Jones A,de Visser SJ,Rissmann R,Burggraaf J

    更新日期:2018-04-01 00:00:00

  • Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.

    abstract:AIMS:To study the effect of eprosartan, a nonbiphenyl tetrazole angiotensin II receptor antagonist, on digoxin pharmacokinetics in a randomized, open-label, two period, period balanced crossover study in 12 healthy men. METHODS:Each subject received a single 0.6 mg oral dose of digoxin (Lanoxicaps 0.2 mg/capsule, Glax...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2125.1997.00608.x

    authors: Martin DE,Tompson D,Boike SC,Tenero D,Ilson B,Citerone D,Jorkasky DK

    更新日期:1997-06-01 00:00:00

  • Anti-hypertensive dose-response effects of nicardipine in stable essential hypertension.

    abstract::The dose-response effects of oral nicardipine on the systemic blood pressure were examined in 54 patients with uncomplicated essential hypertension (DBP greater than or equal to 100 mm Hg). The study was designed in four sequential stages. A 2 week single-blind placebo run-in period was followed by dose titration with...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2125.1985.tb05156.x

    authors: Taylor SH,Frais MA,Lee P,Verma SP,Jackson N,Silke B

    更新日期:1985-01-01 00:00:00

  • Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

    abstract:WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT:Oxycodone is an opioid analgesic that is metabolized mainly in the liver by cytochrome P450 (CYP) 2D6 and 3A4 enzymes. So far, the effects of CYP2D6 or CYP3A4 inhibitors on the pharmacokinetics of oxycodone in humans have not been systematically studied. WHAT THIS STUDY ADDS:Dr...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.2010.03653.x

    authors: Grönlund J,Saari TI,Hagelberg NM,Neuvonen PJ,Olkkola KT,Laine K

    更新日期:2010-07-01 00:00:00

  • Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis.

    abstract:AIMS:Hypertension is a common comorbidity of patients with COVID-19, SARS or HIV infection. Such patients are often concomitantly treated with antiviral and antihypertensive agents, including ritonavir and nifedipine. Since ritonavir is a strong inhibitor of CYP3A and nifedipine is mainly metabolized via CYP3A, the com...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14684

    authors: Niu W,Li S,Jin S,Lin X,Zhang M,Cai W,Jiao Z,Xiang X

    更新日期:2020-12-02 00:00:00

  • Absorption of 5-aminosalicylic acid from colon and rectum.

    abstract::In order to clarify the characteristics of absorption of 5-aminosalicylic acid (5-ASA) from the colon, a neutral solution was instilled into the right part of the colon and the rectum, respectively, in six volunteers. A laxative (bisacodyl) and liquid meals were given prior to each instillation. No significant differe...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1988.tb03301.x

    authors: Bondesen S,Schou JB,Pedersen V,Rafiolsadat Z,Hansen SH,Hvidberg EF

    更新日期:1988-02-01 00:00:00

  • The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial.

    abstract:AIMS:New preventative strategies for stroke are required. One promising strategy is uric acid reduction and xanthine oxidase inhibition with allopurinol. We sought to investigate whether allopurinol improves cerebrovascular reactivity (CVR) following subcortical stroke. METHODS:We performed a randomized, double-blind,...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.2009.03497.x

    authors: Dawson J,Quinn TJ,Harrow C,Lees KR,Walters MR

    更新日期:2009-11-01 00:00:00

  • The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

    abstract:AIMS:To determine the induction effect of rifampicin on the activity of 4'-hydroxylase in poor metabolizers (PMs) with m1 mutation of S-mephenytoin 4'-hydroxylation and the relationship of the effect with gene dose. METHODS:Seven extensive metabolizers (EMs) of S-mephenytoin 4'-hydroxylation and five PMs with m1 mutat...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2125.1998.00643.x

    authors: Feng HJ,Huang SL,Wang W,Zhou HH

    更新日期:1998-01-01 00:00:00

  • Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

    abstract::1. The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the secondary metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the secondary metabolites of omeprazole. 2. The major secondary omeprazole metabolite was the hydroxysulpho...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1994.tb04310.x

    authors: Andersson T,Miners JO,Veronese ME,Birkett DJ

    更新日期:1994-06-01 00:00:00

  • Drug disposition before and after gastric bypass: fenofibrate and posaconazole.

    abstract:AIMS:Roux-en-Y gastric bypass (RYGB) alters the anatomical structure of the gastrointestinal tract, which can result in alterations in drug disposition. The aim of the present study was to evaluate the oral disposition of two compounds belonging to the Biopharmaceutical Classification System Class II - fenofibrate (bil...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1111/bcp.13054

    authors: Gesquiere I,Hens B,Van der Schueren B,Mols R,de Hoon J,Lannoo M,Matthys C,Foulon V,Augustijns P

    更新日期:2016-11-01 00:00:00

  • Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.

    abstract::Twelve healthy volunteers were given orally placebo, itraconazole 100 mg or terbinafine 250 mg for 4 days. Midazolam 7.5 mg was ingested on the fourth day, after which plasma samples were collected and psychomotor performance tests carried out for 17 h. Itraconazole increased the area under the midazolam concentration...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Ahonen J,Olkkola KT,Neuvonen PJ

    更新日期:1995-09-01 00:00:00

  • The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.

    abstract:AIM:Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Because of the large interpatient pharmacokinetic variability and established exposure-response and exposure-toxicity relationships in clinical trial patients, therapeut...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14332

    authors: Westerdijk K,Krens SD,van der Graaf WTA,Mulder SF,van Herpen CML,Smilde T,van Erp NP,Desar IME

    更新日期:2020-05-01 00:00:00

  • Long-term trajectories of medicine use among older adults experiencing polypharmacy in Australia.

    abstract:AIMS:To explore longitudinal changes in the number and type of medicines used among older people who experience polypharmacy. METHODS:We used pharmaceutical claims for a 10% sample of Australian Pharmaceutical Benefits Scheme beneficiaries to identify people aged 70 years and older who were exposed to 5 or more medici...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14504

    authors: Falster MO,Charrier R,Pearson SA,Buckley NA,Daniels B

    更新日期:2020-07-31 00:00:00

  • A framework for simplification of quantitative systems pharmacology models in clinical pharmacology.

    abstract::Quantitative systems pharmacology (QSP) is a relatively new discipline within modelling and simulation that has gained wide attention over the past few years. The application of QSP models spans drug-target identification and validation, through all drug development phases as well as clinical applications. Due to thei...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1111/bcp.14451

    authors: Derbalah A,Al-Sallami H,Hasegawa C,Gulati A,Duffull SB

    更新日期:2020-07-04 00:00:00

  • A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report.

    abstract::1. Preliminary results are reported from a long-term study aimed at recording the concentrations of serum lipids and lipoproteins at 6, 12 and 24 months of treatment with pindolol in young/middle-aged males with moderate hypertension. 2. Seventy-three patients have been recruited, of whom 47 have completed 6 months tr...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1987.tb03272.x

    authors: Carlson LA,Ribacke M,Terent A

    更新日期:1987-01-01 00:00:00

  • Risk factors contributing to a low darunavir plasma concentration.

    abstract::Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir plasma concentrations from January 2010 till December 2014 of hu...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.13464

    authors: Daskapan A,Stienstra Y,Kosterink JGW,Bierman WFW,van der Werf TS,Touw DJ,Alffenaar JC

    更新日期:2018-03-01 00:00:00

  • Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.

    abstract:AIMS:Nicotine nasal spray and transdermal nicotine are effective aids to smoking cessation, and are being evaluated for treatment of other medical diseases. Wide variation in levels of nicotine and its metabolite, cotinine, have been observed with such therapies. This study aimed primarily to assess sources of individu...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.1997.00566.x

    authors: Benowitz NL,Zevin S,Jacob P 3rd

    更新日期:1997-03-01 00:00:00

  • Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

    abstract::The frequency distributions of the 0-8 h urinary metabolic ratios of debrisoquine and mephenytoin were measured in 111 healthy, unrelated Sinhalese resident in Sri Lanka. Blood samples were taken from 77 of these subjects for CYP2D6 genotyping. Bimodality in the distribution of the log10 debrisoquine/4-hydroxydebrisoq...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1994.tb04384.x

    authors: Weerasuriya K,Jayakody RL,Smith CA,Wolf CR,Tucker GT,Lennard MS

    更新日期:1994-11-01 00:00:00

  • Brotizolam and chronic insomnia: a multi-centre study.

    abstract::A double-blind, crossover study was carried out on the acceptability of three doses of brotizolam (0.125, 0.25 and 0.5 mg) in chronic insomniacs aged between 21 and 75 years (33 men: 42 women). Patients reported a shorter time to fall asleep and less nocturnal awakenings. Improvement in sleep was evident during the fi...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2125.1983.tb02319.x

    authors: Fritz-Osner A,Arias-Ortiz JL,Dorantes JF,Rabago-Sánchez J,Rodríguez-Tenorio A,Sánchez-Martinez J

    更新日期:1983-01-01 00:00:00

  • Salbutamol inhibits metabisulphite-induced bronchoconstriction.

    abstract::The effect of salbutamol on bronchoconstriction induced by inhaled sodium metabisulphite has been studied in 12 atopic subjects. Salbutamol (200 micrograms, 3.5 x 10(-7) M) and matched placebo were administered by identical metered dose inhaler 15 min before a dose-response to sodium metabisulphite (1.25-100 mg ml-1) ...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.1991.tb03967.x

    authors: Iredale MJ,Dixon CM,Ind PW

    更新日期:1991-11-01 00:00:00

  • The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.

    abstract::We studied the effect of 3 weeks' treatment with 4 x 200 mg of sulphinpyrazone daily (six healthy volunteers) on proaggregatory thromboxane A2 (TxA2) and antiaggregatory prostacyclin (PGI2). Platelet TxA2 production was evaluated by measuring its stable metabolite, immunoreactive thromboxane B2, from serum, and vessel...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1982.tb02009.x

    authors: Viinikka L,Toivanen J,Ylikorkala O

    更新日期:1982-09-01 00:00:00

  • Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate.

    abstract:AIMS:To compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in hepatically impaired patients and healthy subjects. METHODS:Hepatically impaired patients (n = 11) and healthy subjects (n = 11) were individually paired on the basis of gender, age (+/-10 years) and body weight (+/-20%) and administere...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2125.2005.02340.x

    authors: Snell P,Dave N,Wilson K,Rowell L,Weil A,Galitz L,Robson R

    更新日期:2005-05-01 00:00:00

  • A double-blind multicentre trial comparing mianserin with imipramine.

    abstract::1. Fifty-four depressive in-patients aged 18-45 yr, were treated at random, in double-blind conditions, with mianserin 60 mg daily or imipramine 150 mg daily in three divided doses for 4 weeks. Nitrazepam and diazepam were also allowed if necessary. 2. There was no significant difference in antidepressant efficacy bet...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Pichot P,Dreyfus JF,Pull C

    更新日期:1978-01-01 00:00:00